Skip to content

CONVERT PHARMACEUTICALS

Active Public limited companyfounded 2017active for 9 yearsEsplanade Simone VEIL 1, 4000 LiègeKBO/BCE: BE 0671.828.631

Lifetime

9 annual accounts with figures on one time axis
peak of €202,587 in 2020
-€247,884▲ €266,022
lowest -€1.0m in 2018
-€629,343▲ €16,476
peak of €944,062 in 2017
-€841,823▲ €323,154
€1.8m▼ 25.1%
peak of 5.8 FTE in 2019
-not published
Board4 names since 2017
3 directors and 2 others
Owners
23.32%
Documentsfilings and deeds
17-06-202644 days before the deadline
2025abbreviated format
Gross margin from -€513,906 to -€247,884Loss of €629,343Registered office moved within Liège 29-08Capital increase of €952,497 to €2,222,683 07-07Equity from -€1.2m to -€841,823Debts from €2.4m to €1.8m

Key points

from the 2025 annual accounts

Equity

-€841,823
202020212022202320242025

Debts exceed assets in financial year 2025.

Losses

-€3.0m in six years
-350,0792020-277,2612021-501,4072022-616,3262023-645,8192024-629,3432025

Every financial year from 2020 to 2025 closed with a loss. 2024 was the heaviest.

Debts

€1.8m 189% of the balance sheet
Financial debts 84%Suppliers 16%

Of this, €277,698 falls due within a year.

Liquidity

0.63 was 10.41 in 2024

Short-term debts rose from €54,209 to €277,698.

Position in the sector

-€841,823

Less equity than 93% of companies in research and development. The sector median is €532,346, over 346 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 562 companies had the same profile as CONVERT PHARMACEUTICALS has now. Each dot stands for 2 companies, two years later.

86.8%
were still trading
4.8%
stopped another way
7.1%
went bankrupt
  • Small
  • 5 to 10 years old
  • negative equity
  • a loss of 10% of the balance sheet or more

Another 1.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 562 companies, not a prediction for CONVERT PHARMACEUTICALS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
Director
Director,
  • 23.32%score equity €212.1m (2025) · annual accounts 30-06-2025 of
Board & ownership

Recent changes

2 directors reappointed (director) and (director) · acts as permanent representative · General meeting of 17-09-2026 · Gazette deed
acts as permanent representative reappointed as director · General meeting of 31-07-2026 · Gazette deed
appointed as director General meeting of 01-06-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0671828631
All 28 events

Comparable companies

same main activity, similar in size and age
Company
CONVERT PHARMACEUTICALS Liège €0.9m -€247,884 -89.4% -
BREIN INSTITUUT Antwerp €1.0m -€31,258 98.3% -
Philéole Rixensart €1.0m -€168,479 0.4% 3.1
Plant Bio Technologies Ghent €1.0m -€13,576 23.0% -
Vertiberry Anderlecht €1.8m -€141,558 95.1% 2.4
sil'innov Fleurus €0.5m -€87,325 -139.8% 1.3
4Nature Antwerp €1.0m -€1,521 100.0% -

These companies have the same main activity as CONVERT PHARMACEUTICALS: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €484,000 and €1.8m, founded between 2013 and 2020.

Official details

Source: KBO
Status
Active since 24-02-2017Normal situation
Registered office
107 active companies are registered at this addressOf these, 14 started in the 12 months before 20 November 2026. Source: KBO register, as of 20 November 2026.
Activity
Other research and development on natural sciencesNACE 72109
Establishment unit
2.262.849.1574000 Liège, registered on 24-02-2017
Financial year end
31 December
Peppol
Reachable since 05-12-2025
Company details

Annual accounts 2025

€941,204▼ 22.6%
Filing
Filed on 17-06-2026, 44 days before the end of the filing period
Financials

Insights on CONVERT PHARMACEUTICALS

CONVERT PHARMACEUTICALS files the abbreviated format. That format states no turnover. The gross margin fell from -€26,292 in 2017 to -€247,884 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about CONVERT PHARMACEUTICALS

What is the company number of CONVERT PHARMACEUTICALS?
The company number of CONVERT PHARMACEUTICALS is 0671.828.631. The VAT number is the same number with BE in front: BE 0671.828.631.
Where is CONVERT PHARMACEUTICALS based?
The registered office is at Esplanade Simone VEIL 1, 4000 Liège.Company details
What does CONVERT PHARMACEUTICALS do?
According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of CONVERT PHARMACEUTICALS?
CONVERT PHARMACEUTICALS is a public limited company (NV).
When was CONVERT PHARMACEUTICALS founded?
CONVERT PHARMACEUTICALS was founded on 24-02-2017.
Is CONVERT PHARMACEUTICALS still active?
Yes, CONVERT PHARMACEUTICALS is an active enterprise in the KBO register.
How many employees does CONVERT PHARMACEUTICALS have?
CONVERT PHARMACEUTICALS had an average of 0.3 full-time equivalents in financial year 2023, according to the filed annual accounts.Financials
What is the turnover of CONVERT PHARMACEUTICALS?
The annual accounts for financial year 2025 state no turnover.
Is CONVERT PHARMACEUTICALS profitable?
In financial year 2025, CONVERT PHARMACEUTICALS made a loss of €629,343.
Where can I find the annual accounts of CONVERT PHARMACEUTICALS?
CONVERT PHARMACEUTICALS filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CONVERT PHARMACEUTICALS due?
CONVERT PHARMACEUTICALS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.